Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Published:2014-07 Issue:9940 Volume:384 Page:319-328
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Brose Marcia S,Nutting Christopher M,Jarzab Barbara,Elisei Rossella,Siena Salvatore,Bastholt Lars,de la Fouchardiere Christelle,Pacini Furio,Paschke Ralf,Shong Young Kee,Sherman Steven I,Smit Johannes W A,Chung John,Kappeler Christian,Peña Carol,Molnár István,Schlumberger Martin J

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer;Cooper;Thyroid,2009

2. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma;Shoup;J Am Coll Surg,2003

3. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy;Durante;J Clin Endocrinol Metab,2006

4. Definition and management of radioactive iodine-refractory differentiated thyroid cancer;Schlumberger;Lancet Diabetes Endocrinol,2014

5. Molecular pathogenesis and mechanisms of thyroid cancer;Xing;Nat Rev Cancer,2013

Cited by 1234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thyroid Cancer;JAMA;2024-02-06

2. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review;Frontiers in Endocrinology;2024-01-31

3. Tumor relapse-free survival prognosis related consistency between cancer tissue and adjacent normal tissue in drug repurposing for solid tumor via connectivity map;2024-01-31

4. Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation;Oncotarget;2024-01-24

5. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study;Thyroid®;2024-01-23